MX2021015993A - Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico. - Google Patents

Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico.

Info

Publication number
MX2021015993A
MX2021015993A MX2021015993A MX2021015993A MX2021015993A MX 2021015993 A MX2021015993 A MX 2021015993A MX 2021015993 A MX2021015993 A MX 2021015993A MX 2021015993 A MX2021015993 A MX 2021015993A MX 2021015993 A MX2021015993 A MX 2021015993A
Authority
MX
Mexico
Prior art keywords
combination
leukemia
midostaurine
gilteritinib
venetoclax
Prior art date
Application number
MX2021015993A
Other languages
English (en)
Spanish (es)
Inventor
Kyle Macbeth
De Menezes Daniel E Lopes
Yumin Dai
Mark Frattini
Cl Beach
Shelonitda Rose
Diana R Dunshee
Jessica Jang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2021015993A publication Critical patent/MX2021015993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2021015993A 2019-06-20 2020-06-19 Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico. MX2021015993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962864413P 2019-06-20 2019-06-20
PCT/US2020/038760 WO2020257665A1 (en) 2019-06-20 2020-06-19 Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
MX2021015993A true MX2021015993A (es) 2022-04-06

Family

ID=71528047

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021015993A MX2021015993A (es) 2019-06-20 2020-06-19 Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico.
MX2021015992A MX2021015992A (es) 2019-06-20 2020-06-19 Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015992A MX2021015992A (es) 2019-06-20 2020-06-19 Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.

Country Status (11)

Country Link
US (2) US12447171B2 (cg-RX-API-DMAC10.html)
EP (2) EP3986404A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022537551A (cg-RX-API-DMAC10.html)
KR (2) KR20220050874A (cg-RX-API-DMAC10.html)
CN (2) CN115066243A (cg-RX-API-DMAC10.html)
AU (2) AU2020297596A1 (cg-RX-API-DMAC10.html)
BR (2) BR112021025537A2 (cg-RX-API-DMAC10.html)
CA (2) CA3143711A1 (cg-RX-API-DMAC10.html)
IL (2) IL289115A (cg-RX-API-DMAC10.html)
MX (2) MX2021015993A (cg-RX-API-DMAC10.html)
WO (2) WO2020257671A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US12214054B2 (en) 2015-11-30 2025-02-04 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
EP3443081A4 (en) 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Cpf1に基づくゲノム編集の治療適用
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
TWI887234B (zh) 2019-04-14 2025-06-21 美國公爵大學 治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除
WO2022187288A2 (en) * 2021-03-01 2022-09-09 Duke University Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
JP7898763B2 (ja) * 2021-04-05 2026-08-03 ピノットバイオ インコーポレイテッド 4’-チオ-5-アザ-2’-デオキシシチジンおよびベネトクラクスの併用療法
WO2022240788A1 (en) * 2021-05-11 2022-11-17 Abbvie Inc. Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine
BR112023023677A2 (pt) * 2021-05-11 2024-02-20 Abbvie Inc Regimes de dosagem de venetoclax para o uso no tratamento de síndromes mielodisplásicas em combinação com azacitidina
US20250312327A1 (en) * 2021-10-14 2025-10-09 Pharos Ibio Co., Ltd Composition for combination therapy, comprising 2,3,5-substituted thiophene compound
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CA3260237A1 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
WO2015168466A1 (en) 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
ES2935114T3 (es) 2014-09-05 2023-03-01 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
EA201790543A1 (ru) 2014-09-08 2017-07-31 Селджин Корпорейшн Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
MX373363B (es) 2015-11-05 2020-05-21 Celgene Quanticel Res Inc Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina.
SG10201913290QA (en) * 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2018106984A1 (en) * 2016-12-09 2018-06-14 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療

Also Published As

Publication number Publication date
US12447171B2 (en) 2025-10-21
KR20220024639A (ko) 2022-03-03
AU2020296179A1 (en) 2022-02-03
JP2022537551A (ja) 2022-08-26
BR112021025537A2 (pt) 2022-03-03
WO2020257671A1 (en) 2020-12-24
KR20220050874A (ko) 2022-04-25
CN115066243A (zh) 2022-09-16
JP2022537384A (ja) 2022-08-25
EP3986403A1 (en) 2022-04-27
CN114727996A (zh) 2022-07-08
CA3143711A1 (en) 2020-12-24
IL289115A (en) 2022-02-01
MX2021015992A (es) 2022-04-06
US20220249529A1 (en) 2022-08-11
EP3986404A1 (en) 2022-04-27
WO2020257665A1 (en) 2020-12-24
CA3143719A1 (en) 2020-12-24
BR112021025375A2 (pt) 2022-02-01
AU2020297596A1 (en) 2022-02-03
US20220249528A1 (en) 2022-08-11
IL289110A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
BR112021025375A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para tratamento de leucemia ou síndrome mielodisplástica
MX2019015204A (es) Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda.
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
ZA202202796B (en) Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
CR11687A (es) Terapia de combinación de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada
ECSP17072987A (es) Compuestos nucleósidos 5’-sustituidos
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
CL2022001708A1 (es) Decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis
AR057868A1 (es) Metodos en los que se usa 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona para el tratamiento de ciertas leucemias
PH12019550170A1 (en) Composition comprising oligofructose (of) for use in the improvement of short term memory and other cognitive benefits
ECSP23095641A (es) Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
BR112022012885A2 (pt) Método para tratar um câncer que expressa cd70 em um sujeito, composição farmacêutica para o tratamento de um câncer que expressa cd70, e, kit
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
IL292181B1 (en) Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
ATE534652T1 (de) Phosphono-pent-2-en-1-yl-nukleoside und analoga
MX2018011046A (es) Composiciones y metodos para tratar canceres.
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
MX2009005400A (es) Metodo para el diagnostico y tratamiento del glioma.
CL2017002967A1 (es) Beta-caseinas a2 y capacidad antioxidante.
MX2016010699A (es) Composiciones y metodos para tratar neutropenia.
CL2016000024A1 (es) Volasertib en combinación con decitabina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.
BR112019012106A2 (pt) inibidores de azepano de interação menin-mill
AR057740A1 (es) Cuadro de vehiculo y metodo para su fabricacion